Auris Medical - Model AM-111 - Sonsuvi for Acute Inner Ear Hearing Loss - Datasheet

Auris Medical is developing Sonsuvi for the treatment of acute inner ear (sensorineural) hearing loss (ASNHL). Sonsuvi contains brimapitide, or D-JNKI-1 (D-stereoisomer of c-Jun N-Terminal Kinase Inhibitor 1), an inhibitor of the JNK stress kinase coupled to an intracellular transporter. Sonsuvi is formulated in a biocompatible and fully biodegradable gel and administered in a single dose intratympanic injection into the middle ear. From there the drug diffuses through the round window membrane into the cochlea. Sonsuvi received orphan drug designation from both EMA and FDA for the treatment of ASNHL.